Blind Trials of an Onsite Saliva Drug Test for Marijuana and Opiates

    Volume 46, Issue 5 (September 2001)

    ISSN: 0022-1198

    CODEN: JFSOAD

    Page Count: 7


    Jehanli, A
    Cozart Bioscience Ltd., Abingdon, Oxfordshire, UK

    Moore, L
    Cozart Bioscience Ltd., Abingdon, Oxfordshire, UK

    Brannan, S
    Cozart Bioscience Ltd., Abingdon, Oxfordshire, UK

    Spiehler, VR
    Spiehler Associates, Newport Beach, CA

    (Received 21 June 2000; accepted 9 October 2000)

    Abstract

    The objective of these clinical trials was to calculate the performance, limit of detection, specificity and sensitivity of a novel, semi-quantitative immunoassay for drugs of abuse in saliva and to determine operator bias when measured blind by four different operators. The test is based on lateral flow gold particle technology coupled with digital photography to provide a semi-quantitative end point. The performance of the test was compared with that of enzyme immunoassays and GC/MS methods. Volunteers consumed marijuana or codeine and their saliva was collected 0.25 to 24 h later with the Cozart RapiScan collection device. The sensitivity and specificity of the opiate test were both 100% ± 10.4% for codeine for 9 h after dosing. The cutoff of the marijuana test at 10 ng/mL THCA was too high to detect marijuana use for more than a few hours after smoking. There was no operator bias because the results were presented in written form either as “positive” or “negative for each of the five drug classes on the screen of the hand-held reader.


    Paper ID: JFS15123J

    DOI: 10.1520/JFS15123J

    ASTM International
    is a member of CrossRef.

    Author
    Title Blind Trials of an Onsite Saliva Drug Test for Marijuana and Opiates
    Symposium , 0000-00-00
    Committee E30